{"id":573266,"date":"2025-09-26T00:00:00","date_gmt":"2025-09-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concim0010-2025-biopharma-crohns-disease-china-in-depth-2025\/"},"modified":"2026-05-01T23:16:54","modified_gmt":"2026-05-01T23:16:54","slug":"concim0010-2025-biopharma-crohns-disease-china-in-depth-2025","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concim0010-2025-biopharma-crohns-disease-china-in-depth-2025\/","title":{"rendered":"Crohn&#8217;s Disease | China In-Depth | 2025"},"content":{"rendered":"<p>The Crohn\u2019s disease (CD) therapy market in China is growing rapidly due to the increased prevalence of the disease as a result of urbanization, dietary changes, and better diagnostics. Corticosteroids are essential for managing acute flares, and immunosuppressants are used for long-term maintenance, often alongside biologics. Biologics, particularly anti-TNF agents such as Johnson &#038; Johnson Innovative Medicine\u2019s Remicade and AbbVie\/Eisai\u2019s Humira, are widely used to treat moderate to severe CD. Non-TNF biologics such as Takeda\u2019s Entyvio and Johnson &#038; Johnson Innovative Medicine\u2019s Stelara are options for patients who do not respond to anti-TNF treatment. Recent approvals (e.g., AbbVie\u2019s Skyrizi) and emerging therapies with novel mechanisms of action (e.g., Eli Lilly\u2019s Omvoh, Johnson &#038; Johnson Innovative Medicine\u2019s Tremfya) will expand the treatment armamentarium. This report assesses how clinical and nonclinical factors\u2014such as price dynamics, inclusion in China\u2019s National Reimbursement Drug List (NRDL), and generics or biosimilars\u2014will influence the launch and uptake of key therapies for CD. Understanding these factors will be crucial for the success of current and future players in this lucrative market.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul>\n<li>What is the size of China\u2019s diagnosed CD population, and how will drug-treatment rates change over the forecast period?<\/li>\n<li>What are interviewed experts\u2019 insights into current treatment options?<\/li>\n<li>What are the key unmet needs in the management of CD in China?<\/li>\n<li>What are the key market access considerations for therapies in the CD pipeline in China?<\/li>\n<li>What sales \/ uptake could they secure?<\/li>\n<\/ul>\n<p><strong>Primary research<\/strong><\/p>\n<p>Qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 gastroenterologists in China.<\/p>\n<p><strong>Epidemiology<\/strong><\/p>\n<p>Diagnosed prevalence of Crohn\u2019s disease in urban versus rural China, clinically relevant and market-relevant drug-treatable populations.<\/p>\n<p><strong>Forecast<\/strong><\/p>\n<p>10-year, annualized, drug-level sales and patient share of key Crohn\u2019s disease therapies through 2034, based on primary and secondary market research to formulate bottom-up assumptions.<\/p>\n<p><strong>Drug treatments<\/strong><\/p>\n<p>Coverage of key current and late-phase emerging therapies.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy in China.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.<\/li>\n<li>Gauge the commercial outlook and impact of key market events<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-573266","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573266\/revisions"}],"predecessor-version":[{"id":575325,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573266\/revisions\/575325"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=573266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}